OL
Olema Pharmaceuticals, Inc.
OLMA · NASDAQ
$9.82 -1.06% (-$0.11)
1M -8.14%
Market Cap $898.8M
P/E Ratio -
Div. Yield -
ROE 48.22%
Bulios Fair Price
$9.13
7.0% downside
Current Price
$9.82
Undervalued Fair Value Overvalued
According to Bulios Fair Price, OLMA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
85 /100
Cheap P/B 2.09x
P/E N/A
EV/EBITDA N/A
Growth
100 /100
Growing Book val. growth 34.30%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor ROIC 50.92%
ROE 48.22%
ROA 42.04%
Debt
100 /100
Low Debt/Equity 0.00x
Current ratio 8.86x
Int. coverage N/A
Stability
44 /100
Moderate Beta 1.99x
EPS volatility 11.36%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about OLMA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Sean Bohen
Employees
150
Headquarters
San Francisco
Upcoming events
09 NOV
Earnings
Upcoming earnings report